Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complement activation and diabetic vascular complications.

Jakob Østergaard1, Troels Krarup Hansen, Steffen Thiel

  • 1The Medical Research Laboratories, Clinical Institute, Medical Department M (Diabetes and Endocrinology), Aarhus University Hospital, Nørrebrogade 44, DK-8000 Aarhus C, Denmark.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|July 6, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shaping the future of clinical trials through strategic foresight.

Clinical trials (London, England)·2026
Same author

Circulating 3-hydroxy butyrate predicts mortality in patients with chronic heart failure with reduced ejection fraction.

ESC heart failure·2024
Same author

At any Level of Adiposity, Relatively Elevated Leptin Concentrations Are Associated With Decreased Insulin Sensitivity.

The Journal of clinical endocrinology and metabolism·2023
Same author

Platelets and the Lectin Pathway of Complement Activation in Patients with Systemic Lupus Erythematosus or Antiphospholipid Syndrome.

TH open : companion journal to thrombosis and haemostasis·2023
Same author

Restriction of C1-inhibitor activity in hereditary angioedema by dominant-negative effects of disease-associated SERPING1 gene variants.

The Journal of allergy and clinical immunology·2023
Same author

Inter-α-inhibitor heavy chain H4 and sepsis-related coagulation disturbances: Another link between innate immunity and coagulation.

Research and practice in thrombosis and haemostasis·2023

Diabetic kidney disease, a severe complication, involves the complement system. Research reviews this link, exploring new therapeutic targets for diabetic vascular complications.

Area of Science:

  • Nephrology
  • Immunology
  • Endocrinology

Background:

  • Diabetes mellitus is a growing global health issue.
  • Diabetic nephropathy is a major cause of end-stage renal failure.
  • Existing research implicates glycation, growth factors, and hemodynamics in diabetic kidney disease pathogenesis.

Purpose of the Study:

  • To review the evidence connecting the complement system to vascular dysfunction in diabetes.
  • To specifically focus on the role of the complement system in diabetic kidney disease.
  • To explore potential new therapeutic strategies targeting the complement system.

Main Methods:

  • Literature review of existing research on the complement system and diabetic vascular complications.
  • Analysis of data suggesting the involvement of the MBL pathway of the complement system.

Related Experiment Videos

  • Examination of current therapeutic interventions and their limitations.

    • Main Results:

    • The complement system, particularly the MBL pathway, is increasingly recognized for its role in diabetic vascular complications.
    • Diabetic nephropathy affects a significant percentage of diabetic patients and is a leading cause of renal failure.
    • While therapeutic interventions exist, their effectiveness in preventing diabetic vascular complications is limited.

    Conclusions:

    • The complement system represents a potential therapeutic target for diabetic vascular complications, including diabetic kidney disease.
    • Further research is needed to determine if manipulating the complement system offers effective intervention strategies.
    • Understanding the complement system's role is crucial for developing novel treatments for diabetic kidney disease.